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Background: Adrenal androgen excess is frequently observed in PCOS. The aim of the study was to determine
whether adrenal gland function varies among PCOS phenotypes, women with hyperandrogenism (H) only and
healthy women.
Methods: The study included 119 non-obese patients with PCOS (age: 22.2 ± 4.1y, BMI:22.5 ± 3.1 kg/m2), 24 women
with H only and 39 age and BMI- matched controls. Among women with PCOS, 50 had H, oligo-anovulation (O),
and polycystic ovaries (P) (PHO), 32 had O and H (OH), 23 had P and H (PH), and 14 had P and O (PO). Total
testosterone (T), SHBG and DHEAS levels at basal and serum 17-hydroxprogesterone (17-OHP), androstenedione
(A4), DHEA and cortisol levels after ACTH stimulation were measured.
Results: T, FAI and DHEAS, and basal and AUC values for 17-OHP and A4 were significantly and similarly higher in
PCOS and H groups than controls (p < 0.05 for all) whereas three groups did not differ for basal or AUC values of
DHEA and cortisol. Three hyperandrogenic subphenotypes (PHO, OH, and PH) compared to non-hyperandrogenic
subphenotype (PO) had significantly and similarly higher T, FAI, DHEAS and AUC values for 17-OHP, A4 and DHEA
(p < 0.05). All subphenotypes had similar basal and AUC values for cortisol.
Conclusion: PCOS patients and women with H only have similar and higher basal and stimulated adrenal
androgen levels than controls. All three hyperandrogenic subphenotypes of PCOS exhibit similar and higher basal
and stimulated adrenal androgen secretion patterns compared to non-hyperandrogenic subphenotype.
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Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder of reproductive-aged women with an
estimated prevalence of 6-7% [1]. PCOS is characterized
by androgen excess, oligo-anovulation (O) and polycystic
ovaries (P). Since it’s a heterogeneous disorder, several
criteria have been proposed for its diagnosis [2,3].
According to 1990 National Institutes of Health (NIH)
criteria, the presence of both oligo-and/or anovulation
and clinical (hirsutism) and /or biochemical signs of
hyperandrogenism (H) are needed, regardless of the pres-
ence of P on ultrasound [2]. Due to the lack of agreement* Correspondence: yildizbo@yahoo.com
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reproduction in any medium, provided the oron standardized criteria to make the diagnosis of PCOS,
an international consensus workshop in Rotterdam, spon-
sored by The American Society for Reproductive Medicine
(ASRM) and European Society for Human Reproduction
and Embryology (ESHRE) expanded the diagnostic criteria
for PCOS with the addition of the ultrasound assesment of
ovarian morphology [3]. According to these new criteria,
PCOS can be defined when at least two of the three fea-
tures (O,H and P) are present. Using these Rotterdam cri-
teria, four phenotypes of PCOS are identified (i.e.) PHO
(phenotype1), OH (phenotype 2), PH (phenotype 3) and
PO (phenotype 4).
While the ovaries are the main source of androgen
excess in PCOS, excess adrenal androgen (AA) levels
and adrenocortical dysfunction have been reported in
many PCOS patients [4-7]. Elevated serum levels oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hydroxyandrostenedione (11-OHA4) is found in 20-
50% of patients with PCOS [4,6]. PCOS women show a
generalized hypersecretion of adrenocortical products,
basally and in response to ACTH including pregneno-
lone, 17-hydroxypregnenolone, dehydroepiandrosterone
(DHEA), androstenedione (A4) and possibly cortisol (F) [8].
Peripubertal AA excess is associated with the develop-
ment of PCOS-like symptomatology in patients with 21-
hydroxylase deficient classic and non-classic adrenal
hyperplasia [9,10]. Patients with PCOS have a greater in-
cidence of exaggerated AA secretion during the peripu-
bertal period [11] and patients with premature adrenarche
are at higher risk for the development of PCOS [12].
Moreover, women with PCOS exhibit enhanced adrenal
androgen production over long time [13,14] and increased
DHEAS levels were reported in sisters [15] of PCOS
patients suggesting that inheritance plays a significant role
in AA secretion of PCOS.
Previous data suggest that adrenocortical excess in
PCOS might result in different phenotypic features
(e.g. acne) [16]. Recently, differences in metabolic charac-
teristics and basal AA levels of the subphenotypes of
PCOS have been reported indicating phenotype PO as the
mildest expression of the PCOS spectrum [17,18]. We
now hypothesize that AA excess will be less pronounced
in the phenotype PO of PCOS and will be more associated
with hyperandrogenic phenotypes. To test our hypothesis,
we determine the differences in AA production in re-
sponse to ACTH stimulation among different phenotypes
of PCOS according to Rotterdam criteria, women with H
only and healthy women.
Materials and methods
Subjects
A total of 143 consecutive non-obese patients (BMI <
30 kg/m2), who attended to the Outpatient Clinic of
Endocrinology and Metabolism of Hacettepe University
between January 1 2006 and December 31 2010 were
prospectively enrolled in the study. Among the patients,
50 had H, O and P (PHO), 32 had H and O without P
(OH), 23 had H and P with normal menses (PH), 14 had
O and P (PO) and 24 women with H only. All patients
fulfilled the diagnostic criteria for PCOS according to
revised 2003 Rotterdam criteria [3]. H was defined as
having hirsutism (modified Ferriman-Gallwey score ≥ 6)
and/or a total testosterone (T) and/or free androgen
index (FAI) level above the upper 95th percentile of 110
healthy non-hirsute eumenorrheic women. Specifically
the upper normal limits were as follows: total T,
60 ng/dl (2.08 nmol/liter) and FAI, 4.94. Ovulatory
dysfunction was defined as menstrual cycles ≥35 or
≤23 days. In patients with hirsutism or P appearance
who had apparently regular menstrual bleeding, lutealphase (Days 21–24) progesterone levels were deter-
mined and the threshold for the presence of ovulation
was taken as 4 ng/ml (12.7 nmol/liter). P was defined
as the presence of ≥12 follicles in an ovary measuring
2–9 mm in diameter and/or increased ovarian volume
(>10 mL) at least in a single ovary [3]. Women with a
secondary endocrine disorder, such as hyperprolacti-
naemia, non-classical form of congenital adrenal hyper-
plasia, thyroid function disorder and androgen secreting
tumors were excluded as suggested [3]. Thirty-nine
age- and BMI- matched healthy women without fea-
tures of H, O or P formed the control group. None of
the subjects were taking any hormonal medication in-
cluding oral contraceptive pills for at least 3 months
before the study.
The study was approved by the Local Ethics Commit-
tee of the Hacettepe University School of Medicine and
informed consent was obtained from all subjects.
Study protocol
All participants were evaluated by means of a standar-
dized form that includes a medical history and physical
examination. Weight, height, waist and hip circumfe-
rences (waist: midway between the lower rib margin
and the iliac crest, hip: widest circumference over the
great trochanters) were measured. The body mass index
[BMI; weight (kilograms)/ height (meters) 2] and waist
to hip ratio (WHR) were calculated. Hirsutism was
evaluated by modified Ferriman-Gallwey scoring (mFG)
system.
All subjects were studied during the follicular phase of
the menstrual cycle (2–5 days after onset of last spon-
taneous or progestin-induced menstrual bleeding). Basal
blood samples were obtained for hormonal and meta-
bolic parameters. Hormonal and metabolic evaluation
included T, A4, DHEAS and sex hormone-binding
globulin (SHBG), fasting plasma glucose (FPG) and insu-
lin. Free androgen index (FAI = [testosterone (nmol/L)/
SHBG(nmol/L)]x100) and homeostatic model assesment
of insulin resistance (HOMA-IR = [fasting insulin
(μU/ml)x fasting plasma glucose (FPG) (mmol/L)]/22.5)
were calculated as previously described [19].
All participants underwent short ACTH stimulation
test. 0.25 mg ACTH-(1-24) (Synacthen 0.25 mg/1 ml;
Defiante Farmaceutica, S.A., Portugal) was administered
IV over 60 sec. and blood samples were drawn for serum
F, 17-OHP, A4 and DHEA levels 1 min. before and 30
and 60 min. after ACTH administration. Areas under
the curve (AUC), and delta max values for 17-OHP, A4,
DHEA and F responses were calculated.
Assays
Blood samples were taken through venepuncture and
centrifuged within 2 h after withdrawal. Serum was
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and insulin concentrations were measured by chemilumi-
niscent immunoassay kits (Roche Diagnostics GmbH,
Mannheim, Germany). SHBG was measured by using
immunoradiometric assay (ZenTech, Angleur, Belgium).
Plasma glucose concentration was determined by the glu-
cose oxidase method (Olympus AU 2700, Beckmann,
Coulter, Inc., MA, USA). The concentration of DHEAS
and A4 were determined by chemiluminiscent immuno-
assay (ImmuliteW 2000, Los Angeles, USA). Serum DHEA
level was measured using a solid phase enzyme-linked
immunosorbent assay (DRG Instruments, Marburg,
Germany). 17-OHP was measured by radioimmuno-
assay kit from Immunotech.Statistical analysis
Differences in basal characteristics and laboratory data
among the groups were analyzed by one-way analysis
of variance (ANOVA) and post hoc Tukey test for
dual-wise comparisons for normally distributed para-
meters, and Kruskal-Wallis one-way ANOVA and
Mann–Whitney test for dual-wise comparisons for
parameters with skewed distribution. By using the trap-
ezoidal method, 17-OHP, A4, DHEA and F responses
to ACTH stimulation were expressed as AUC. Pearson/
Spearman correlations were used to examine the rela-
tionship between DHEAS levels and fasting insulin and
HOMA-IR values. Statistical Package for Social Sciences,
version 15.0 (SPSS Inc., Chicago) was used for analyses.
Values were described as mean ± SD and P < 0.05 was




Age (year) 22.2 ± 4.1
BMI (kg/m2) 22.5 ± 3.1
WHR 0.76 ± 0.06
mFG 8.7 ± 5.3ª
Testosterone (ng/dl) 70.4 ± 34.5ª
SHBG (nmol/l) 39.6 ± 20.7ª
FAI 8.8 ± 7.6ª
DHEAS (μg/dl) 278 ±134b
FPG (mg/dl) 82.4 ± 11.8
Fasting insulin (μIU/ml) 11.1 ± 5.9
HOMA-IR 2.3 ± 1.3
Results are expressed as mean ± SD. NS not significant, BMI body mass index, WHR
binding globulin, FAI free androgen index, DHEAS dehydroepiandrosterone sulfate,
resistance.
a P <0.001 vs. Control.
b P <0.01 vs. Control.Results
The basal characteristics of the PCOS, H only and control
groups are shown in Table 1. No significant difference in
the basal characteristics was observed between PCOS and
H only group (Table 1, NS for all). The mean levels of T,
FAI and DHEAS were significantly higher in PCOS and H
only group than controls (Table 1, P < 0.001 for all). There
was no significant difference in FPG, fasting insulin and
HOMA-IR values among the groups (Table 1, NS for all).
Basal, stimulated and AUC values for 17-OHP and A4
were significantly and similarly higher in PCOS and H
only groups than controls (Table 2, P < 0.01 for all)
whereas three groups did not differ for basal, stimulated
or AUC values of DHEA and F (Table 2, NS for all). Also,
delta max AA responses to ACTH were evaluated and
PCOS and H only group had higher values for 17OHP
and A4 than controls (P < 0.05 for all, data not shown).
Table 3 shows the comparisons of clinical and hormonal
characteristics among different phenotypes of PCOS. All
the phenotypes had similar mean age, BMI and WHR
values (Table 3, NS for all). Within the PCOS group, 3
hyperandrogenic subphenotypes (PHO, OH and PH)
compared to non-hyperandrogenic subphenotype (PO)
had significantly and similarly higher T, FAI, DHEAS
(Table 3, P < 0.001 for all). While there was no significant
difference in FPG levels among the groups (Table 3, NS), a
significant difference in fasting insulin levels and HOMA-
IR values between PHO, OH and PH groups was observed
(Table 3, P < 0.01 for all). Stimulated and AUC values for
17-OHP and A4 were significantly higher in 3 hyperan-
drogenic subphenotypes (PHO, OH and PH) than non-
hyperandrogenic subphenotype (PO) (Table 4, P < 0.05 foromen with PCOS, women with H only and control
H Control P
(n = 24) (n = 39) (overall)
23.8 ± 4.9 24.4 ± 2.9 NS
22.1 ± 2.3 21.2 ± 2.08 NS
0.77 ± 0.04 0.75 ± 0.06 NS
10.0 ± 3.4ª 0.6 ± 0.9 <0.001
70.3 ± 30.7ª 34.9 ± 11.6 <0.001
32.8 ± 16.7ª 56.5 ± 29.1 <0.001
8.5 ± 4.5ª 2.7 ± 1.6 <0.001
314 ± 115ª 204 ± 74 <0.001
81.2 ± 10.7 83.7 ± 11.2 NS
9.2 ± 3.5 9.4 ± 3.1 NS
1.8 ± 0.7 1.9 ± 0.7 NS
waist-to-hip ratio, mFG modified Ferriman-Gallwey score, SHBG sex hormone-
FPG fasting plasma glucose, HOMA-IR homeostatic model assesment of insulin
Table 2 ACTH stimulated hormone levels and their AUC values in patients with PCOS, women with H only and control
groups
Parameters PCOS H Control P
(n = 119) (n = 24) (n = 39) (overall)
DHEA0 16.7 ± 7.9 20.7 ± 8.9 14.5 ± 5.9 NS
DHEA30 23.8 ± 6.8 25.2 ± 6.2 21.5 ± 6.3 NS
DHEA60 25.4 ± 6.3 26.3 ± 6.0 24.6 ± 6.3 NS
17-OHP 0 (ng/ml) 1.5 ± 0.9
b 1.6 ± 0.7b 1.1 ± 0.7 <0.01
17-OHP30 (ng/ml) 3.5 ± 1.5
b 3.4 ± 0.9c 2.8 ± 1.2 <0.01
17-OHP60 (ng/ml) 4.1 ± 1.7
b 3.9 ± 0.9b 3.2 ± 1.1 <0.01
A40 (ng/ml) 3.1 ± 1.5
a 3.2 ± 1.2b 2.2 ± 0.9 <0.001
A430 (ng/ml) 4.0 ± 1.8
a 4.0 ± 1.2b 2.8 ± 0.9 <0.001
A460 (ng/ml) 4.3 ± 1.7
a 4.1 ± 1.2b 3.1 ± 0.9 <0.001
F0 (μg/dl) 13.9 ± 5.8 15.9 ± 7.6 14.0 ± 5.4 NS
F30 (μg/dl) 26.5 ± 5.0 26.2 ± 5.4 25.9 ± 4.5 NS
F60 (μg/dl) 30.9 ± 6.1 30.8 ± 6.4 30.6 ± 5.0 NS
AUCDHEA (ng/ml × 60 min) 1338 ± 375 1459 ± 375 1227 ± 351 NS
AUC17-OHP (ng/ml × 60 min) 190 ± 80
b 183 ± 44b 148 ± 60 <0.01
AUCA4 (ng/ml × 60 min) 232 ± 99
a 229 ± 69c 165 ± 53 <0.001
AUCF (μg/dl × 60 min) 1471 ± 303 1487 ± 361 1446 ± 258 NS
Results are expressed as mean ± SD. NS not significant, AUC area under the curve, DHEA dehydroepiandrosterone, 17-OHP 17-hydroxyprogesterone, A4
androstenedione, F cortisol.
a P <0.001 vs. Control.
b P <0.01 vs. Control.
c P <0.05 vs. Control.
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AUC values for F (Table 4, NS for all). Basal, stimulated
and AUC values for DHEA in OH and PH groups were
significantly higher than those in PO group (Table 4, P <
0.05 for all).Table 3 Comparisons of clinical and hormonal characteristics
Parameters PHO OH
(n = 50) (n = 32)
Age (year) 22.4 ± 4.5 22.4 ± 4.3
BMI (kg/m2) 22.6 ± 3.1 22.7 ± 3.2
WHR 0.78 ± 0.05 0.77 ± 0.05
mFG 8.2 ± 5.0a,* 10.9 ± 5.1a
Testosterone (ng/dl) 74.8 ± 37.6a 77.9 ± 30.8a
SHBG (nmol/l) 39.9 ± 23.5 36.9 ± 17.8
FAI 9.9 ± 8.4a 9.6 ± 8.0a
DHEAS (μg/dl) 277 ± 127 b 312 ±140b
FPG (mg/dl) 82.0 ± 12.6 81.4 ± 11.5
Fasting insulin (μIU/ml) 12.3 ± 7.5c 11.2 ± 3.7c
HOMA-IR 2.6 ± 1.6c 2.3 ± 0.8c
Results are expressed as mean ± SD. NS not significant, PHO polycystic ovaries, olig
hyperandrogenism, PH polycystic ovaries and hyperandrogenism, PO polycystic ova
modified Ferriman-Gallwey score, SHBG sex hormone-binding globulin, FAI free and
glucose, HOMA-IR homeostatic model assesment of insulin resistance.
a P <0.001 vs. PO.
b P <0.01 vs. PO.
c P <0.01 vs. PH.
*P =0.05 vs. OH.To evaluate the prevalence of AA excess in the study
groups, DHEAS levels were log transformed to satisfy
the assumption of the normal distribution and the upper
95% normative value for log DHEAS for control group
was calculated. 95th percentile log DHEAS value in theamong different phenotypes of PCOS
PH PO P
(n = 23) (n = 14) (overall)
22.3 ± 3.3 20.8 ± 3.4 NS
22.1 ± 2.9 22.5 ± 4.04 NS
0.75 ± 0.06 0.77 ± 0.07 NS
10.6 ± 3.6a 1.4 ± 1.7 <0.001
71.7 ± 29.1a 35.9 ± 15.7 <0.001
38.6 ± 20.7 46.0 ± 15.7 NS
8.8 ± 5.8b 2.8 ± 1.4 <0.01
294 ± 136b 174.9 ± 95.8 <0.01
83.1 ± 9.3 84.9 ± 14.4 NS
8.2 ± 4.1 10.2 ± 4.9 <0.01
1.7 ± 0.9 2.3 ± 1.2 <0.05
o-anovulation and hyperandrogenism, OH oligo-anovulation and
ries and oligo-anovulation, BMI body mass index, WHR waist-to-hip ratio, mFG
rogen index, DHEAS dehydroepiandrosterone sulfate, FPG fasting plasma
Table 4 ACTH stimulated hormone levels and their AUC values among different phenotypes of PCOS
Parameters PHO OH PH PO P
(n = 50) (n = 32) (n = 23) (n = 14) (overall)
DHEA0 15.9 ± 7.9 19.3 ± 7.7
a 17.2 ± 7.3b 12.2 ± 7.5 <0.05
DHEA30 23.7 ± 6.7
b 24.9 ± 6.7a 25.5 ± 5.5a 18.2 ± 6.4 <0.05
DHEA60 24.7 ± 6.3* 27.2 ± 5.9
b 26.3 ± 5.2 21.8 ± 8.1 <0.05
17-OHP0 (ng/ml) 1.6 ± 1.1 1.4 ± 0.7 1.6 ± 1.3 0.9 ± 0.3 0.078
17-OHP30 (ng/ml) 3.7 ± 1.7
b 3.7 ± 1.2a 3.6 ± 1.5b 2.6 ± 1.1 <0.05
17-OHP60 (ng/ml) 4.3 ± 1.9 4.2 ± 1.5 4.3 ± 1.8 3.1 ± 1.1 0.072
A40 (ng/ml) 3.4 ± 1.9 3.2 ± 1.2 2.8 ± 0.8 2.2 ± 1.0 NS
A430 (ng/ml) 4.3 ± 2.0
a 4.3 ± 1.8b 4.0 ± 1.3b 2.9 ± 0.9 <0.05
A460 (ng/ml) 4.7 ± 1.9
a 4.3 ± 1.7b 4.4 ± 1.4a 3.1 ± 1.0 <0.01
F0 (μg/dl) 14.4 ± 6.3 14.6 ± 6.0 13.9 ± 5.6 11.6 ± 4.4 NS
F30 (μg/dl) 26.2 ± 4.6 28.6 ± 5.1 25.9 ± 6.1 25.2 ± 4.6 NS
F60 (μg/dl) 30.4 ± 6.7 32.3 ± 5.7 31.5 ± 5.9 29.5 ± 5.5 NS
AUCDHEA (ng/ml × 60 min) 1314 ± 390 1437 ± 348
a 1415 ± 297a 1057 ± 397 <0.05
AUC17-OHP (ng/ml × 60 min) 198 ± 90
a 195 ± 62a 194 ± 85b 140 ± 51 <0.05
AUCA4 (ng/ml × 60 min) 254 ± 117
a 240 ± 93b 230 ± 69a 164 ± 55 <0.05
AUCF (μg/dl × 60 min) 1466 ± 312 1563 ± 298 1456 ± 331 1372 ± 253 NS
Results are expressed as mean ± SD. NS not significant, AUC area under the curve, PHO polycystic ovaries, oligo-anovulation and hyperandrogenism, OH oligo-
anovulation and hyperandrogenism, PH polycystic ovaries and hyperandrogenism, PO polycystic ovaries and oligo-anovulation, DHEA, dehydroepiandrosterone,
17-OHP 17-hydroxyprogesterone, A4 androstenedione, F cortisol.
a P <0.01 vs. PO.
b P <0.05 vs. PO.
*P <0.05 vs. OH.
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supranormal DHEAS levels were 27.6% in PCOS, 33.3%
in H only group and 2.6% in the control group respect-
ively. PCOS and H only groups had significantly higher
rates of AA excess than controls (27.6%, 33.3% and 2.6%
respectively; P < 0.05) while the two groups did not differ
in comparison. Among the PCOS phenotypes, PHO and
OH group had non-significantly higher rates of AA excess
than non-hyperandrogenic subphenotype (PO) (PHO
31.3% vs PO 7.1% P = 0.09; OH 34.4% vs PO 7.1% P =
0.073) whereas no significant difference was observed be-
tween PH and PO group (22.7% vs 7.1% respectively, NS).
DHEAS levels did not show any correlation with fast-
ing insulin or HOMA-IR values in PCOS, H only or
control groups or in subphenotype groups of PCOS (NS,
data not shown).
Discussion
In this study, we report adrenocortical steroid response
to ACTH among patients with different phenotypes of
PCOS according to Rotterdam criteria, women with H
only and healthy women. Our data indicate that non-
obese patients with PCOS and women with H only have
similar adrenal responses that differ from age- and BMI-
matched healthy women with higher basal DHEAS, and
higher 17-OHP and A4 levels both basally and in re-
sponse to ACTH. Even though hyperandrogenism was
defined by the presence of hirsutism and/or increasedFAI in this study, all three hyperandrogenic subpheno-
types exhibited similar AA secretion patterns with
higher DHEAS, and higher 17-OHP and A4 responses
to ACTH stimulation compared to non-hyperandrogenic
subphenotype. Similar basal DHEA levels in PCOS, H
only and control women despite higher DHEAS values
in PCOS and H only groups compared to healthy
women might suggest differences in the expression of
DHEA-sulfotransferase activity.
Adrenarche is the maturation of the zona reticularis of
the adrenal gland with increase in AAs in early puberty.
Premature and/or exaggerated adrenarche is reported to
be associated with the development of PCOS in a num-
ber of studies [20,21]. Regarding the role of AAs in the
pathophysiology of PCOS, adrenal function during child-
hood and pubertal development in daughters of women
with PCOS was studied [22]. In this study, increased
DHEAS serum concentrations and biochemical evidence
of an exacerbated adrenarche was observed in daughters
of women with PCOS suggesting these features as an
early step in the development of PCOS [22]. Moreover,
adrenocortical excess in PCOS might result in different
phenotypic features (e.g.acne) [16]. It is also important
to note that the alterations in androgen levels with aging
in PCOS might result in changes in phenotypic expres-
sion of the syndrome (i.e. decrease in prevalence of
hyperandrogenic phenotypes) [23]. Our data suggest that
hyperandrogenic subphenotypes of PCOS have increased
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DHEAS levels and higher AA response to ACTH stimu-
lation compared to non-hyperandrogenic subphenotype.
Taken together, it might be postulated that the subjects
who exposed to premature and/or exaggerated adre-
narche during pubertal development might present with
hyperandrogenic phenotypes of PCOS later in life and
AAs might play role in the clinical presentation and
phenotypic expression of PCOS.
Enhanced secretory response of A4, 17-OHP and
DHEA after ACTH stimulation in women with PCOS
defined by NIH criteria was shown in the previous stu-
dies [24-26]. Conflicting results are also available even
in studies using the same NIH criteria [27,28]. For ex-
ample, Erel et al. showed that AA response to ACTH
was similar between women with PCOS and controls
[27], whereas Kamel et al. reported that PCOS patients
(n = 29) had higher basal and stimulated DHEAS, 17-
OHP and stimulated F levels than idiopathic hirsutism
(IH) (n = 21) and control (n = 20) subjects [28]. Evalua-
ting potential differences of AA excess among various
PCOS subphenotypes we now provide data supporting
the hypothesis that AA excess both basally and in
reponse to ACTH is more associated with hyperandro-
genic PCOS and is not a prominent feature of the
phenotype formed by ovulatory dysfunction and poly-
cystic ovaries. Our data are in line wih previous work in
that basal and stimulated cortisol levels in PCOS are
similar with healthy women [29]. Furthermore, cortisol
responses to ACTH appear to be similar in subpheno-
types of PCOS as well.
Prevalence of AA excess defined by supranormal
DHEAS levels in PCOS is between 20-30% . Carmina
et al. reported similar prevalence of AA excess deter-
mined by elevations of DHEAS in idiopathic hyperan-
drogenism (IHA), classic PCOS and ovulatory PCOS
(PH) (48.3%, 36.7% and 29.1% respectively, NS) [30]. We
have found similar rates of AA excess in PCOS, H only
patients and among hyperandrogenic phenotypes of
PCOS (PHO, OH, PH).
IHA, a diagnosis exclusion, is the second most com-
mon androgen disorder. Adrenal hyperandrogenism is
common in these patients. Almost 50% of the patients
with IHA were reported to have elevated circulating
DHEAS levels [30]. An isolated increase of DHEAS
levels was found in 7% of the patients and ovarian
source of the androgens was found in 90% of the
patients associated with exaggerated AA production in
about half of them [30,31]. Atmaca et al. showed that
peak and AUC responses of 11-deoxy-cortisol, DHEAS
and A4 to ACTH were significantly higher in IHA
patients than controls [32]. These data are in line with
our finding of similar adrenal hyperfunction in PCOS
and H only groups that were higher than controls.Comparison of endocrine and metabolic characteris-
tics of the different phenotypes of PCOS were studied in
several studies [17,18,33,34] . Panidis et al. reported that
circulating androgens were higher in PCOS patients with
hyperandrogenic subphenotypes (PHO, OH and PH)
compared with those with non-hyperandrogenic subphe-
notype (PO) [17]. Kauffman et al. also showed that tes-
tosterone and DHEAS levels were highest in PHO and
OH phenotype and the androgen levels were indistin-
guishable in PO than controls [33]. These results suggest
that androgen production is the most prominent endo-
crine and metabolic factor differentiating phenotypic
expressions of PCOS and phenotype PO is the mildest
expression of the PCOS spectrum. In accordance with
these data, we have found that AA excess both basally
and in response to ACTH was less pronounced in the
phenotype PO of PCOS and more associated with hyper-
androgenic phenotypes.
Conflicting data are available regarding potential inter-
action between glucose/insulin axis and adrenocortical
dysfunction in PCOS. Hyperinsulinemia in PCOS stimu-
lates androgen secretion by ovarian theca cells and
increases the hormonally active free androgen fraction
by reducing the hepatic production of SHBG [35]. Insu-
lin sensitizing agents such as metformin causes a de-
crease in serum androgen levels with improvement in
insulin sensivity parameters [36]. In a study including
1212 women with PCOS and 254 healthy women,
phenotype PHO was found to be associated with more
IR than other phenotypes [17]. Obese patients with OH
and PO phenotype were also characterized with IR
whereas phenotype PH was not associated with IR. No
significant association was reported between DHEAS
levels and fasting insulin in some studies [37] whereas
high DHEAS levels were reported to be negatively corre-
lated to insulin resistance in others [16,38,39]. Moreover,
it was demonstrated that hyperinsulinemia potentiates
ACTH-stimulated androgen production in women with
PCOS [40]. Regarding the association between insulin
resistance and hyperandrogenism, studies with insulin
sensitizers such as thiazolidinediones or metformin
showed that significant reductions were observed in the
secretion of A4 and 17-OHP in response to ACTH
stimulation [41,42]. On the other hand, adrenocortical
biosynthesis, basally and in response to ACTH, are
thought to be associated with glucose-mediated glucose
disposal rather than the degree of hyperinsulinemia or
insulin-mediated glucose disposal [43]. In our study, we
have failed to show any difference in insulin resistance
parameters between PCOS patients and controls, and a
relationship between DHEAS levels and fasting insulin
or HOMA-IR values. Normal BMI and relatively young
age of the participants might in part explain our finding
of a non-significant difference in fasting insulin and
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http://www.ovarianresearch.com/content/5/1/42HOMA-IR values between patients and controls. Alter-
natively, we might have failed to detect a difference due
to insensitivity of the fasting measurements we have
used. Obesity may affect adrenocortical function by de-
creasing insulin sensitivity and inducing the secretion of
adipocytokines. Available literature suggests that hyper-
secretion of F and possibly A4 and DHEA are observed
in obese healthy women [44] although conflicting results
are also reported [45]. Our study design precludes us
from any potential confounding effect of obesity since
only lean women participated in the study.
A limitation of our study is the relatively small sample
size of the groups with each phenotype. Secondly, we
were not able to assess potential ovarian contribution to
androgen synthesis since we did not use a GnRH analogue.
Thirdly, our results could not be extrapolated to obese
women with PCOS or PCOS patients of different races.
In conclusion, our data suggest that in PCOS patients
and women with H only, basal and ACTH-stimulated
AA levels are similar and higher than those in healthy
women. All three hyperandrogenic subphenotypes of
PCOS exhibit similar and higher basal and ACTH-
stimulated AA secretion patterns compared to non-
hyperandrogenic subphenotype. AA excess appears to be
more associated with hyperandrogenism and is less pro-
nounced in women with ovulatory dysfunction and poly-
cystic ovaries. Similar AA production in women with H
only and hyperandrogenic subphenotypes of PCOS sug-
gest that this group might be a spectrum of PCOS and
might develop the syndrome at a later time. Understand-
ing the regulation of adrenal steroidogenesis in subphe-
notypes of PCOS might provide novel mechanistic
insights into the pathophysiology and developmental
context of the syndrome.
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